Immunotoxin treatment of cancer

被引：302

作者：

Pastan, Ira ^{[1
]}

Hassan, Raffit ^{[1
]}

FitzGerald, David J. ^{[1
]}

Kreitman, Robert J. ^{[1
]}

机构：

[1] NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2007年 / 58卷

关键词：

Pseudomonas toxin; diphtheria toxin; monoclonal antibody; recombinant immunotoxin;

D O I：

10.1146/annurev.med.58.070605.115320

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Immunotoxms are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.

引用

页码：221 / 237

页数：21

共 101 条

[11]

BREGNI M, 1989, BLOOD, V73, P753

[12] B3(FV)-PE38KDEL, A SINGLE-CHAIN IMMUNOTOXIN THAT CAUSES COMPLETE REGRESSION OF A HUMAN CARCINOMA IN MICE [J].

BRINKMANN, U ;

PAI, LH ;

FITZGERALD, DJ ;

WILLINGHAM, M ;

PASTAN, I .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8616-8620

[13]

BYERS VS, 1989, CANCER RES, V49, P6153

[14] A RECOMBINANT IMMUNOTOXIN CONSISTING OF 2 ANTIBODY VARIABLE DOMAINS FUSED TO PSEUDOMONAS EXOTOXIN [J].

CHAUDHARY, VK ;

QUEEN, C ;

JUNGHANS, RP ;

WALDMANN, TA ;

FITZGERALD, DJ ;

PASTAN, I .

NATURE, 1989, 339 (6223) :394-397

[15]

CHIRON MF, 1994, J BIOL CHEM, V269, P18167

[16] Improving antibody affinity by mimicking somatic hypermutation in vitro [J].

Chowdhury, PS ;

Pastan, I .

NATURE BIOTECHNOLOGY, 1999, 17 (06) :568-572

[17] Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition [J].

Dälken, B ;

Giesübel, U ;

Knauer, SK ;

Wels, WS .

CELL DEATH AND DIFFERENTIATION, 2006, 13 (04) :576-585

[18] Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma [J].

Dang, NH ;

Hagemeister, FB ;

Pro, B ;

McLaughlin, P ;

Romaguera, JE ;

Jones, D ;

Samuels, B ;

Samaniego, F ;

Younes, A ;

Wang, M ;

Goy, A ;

Rodriguez, MA ;

Walker, PL ;

Arredondo, Y ;

Tong, AT ;

Fayad, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4095-4102

[19] Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK®) [J].

Duvic, M ;

Kuzel, T ;

Olsen, EA ;

Martin, AG ;

Foss, FM ;

Kim, YH ;

Heald, PW ;

Bacha, P ;

Nichols, J ;

Liepa, A .

CLINICAL LYMPHOMA, 2002, 2 (04) :222-228

[20]

Fidias Panos, 2002, Clin Lung Cancer, V3, P219, DOI 10.3816/CLC.2002.n.006

← 1 2 3 4 5 6 7 8 9 10 →